RDHL
Redhill Biopharma·NASDAQ
--
--(--)
--
--(--)
RDHL Profile
Redhill Biopharma Ltd.
A specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases
Pharmaceutical
08/03/2009
12/26/2012
NASDAQ Stock Exchange
35
12-31
Depository Receipts (Ordinary Shares)
21 Ha’arba’a Street, Tel Aviv 6473921, Israel
--
Redhill Biopharma Ltd., was incorporated in Israel on August 3, 2009. The company is a specialty biopharmaceutical company focused on gastrointestinal and infectious diseases. The company's primary objective is to become a leading specialty biopharmaceutical company through its commercial presence in the United States, supporting the commercialization of existing and potential other products marketed in the United States, as well as the commercialization of possible future therapeutic candidates, if approved. The company is currently focusing on the commercialization of GI-related products Talicia (omeprazole, amoxicillin and rifabutin) and Aemcolo (rifamycin) in the United States.
